Cardioprotective effect of N-(benzo[d]oxazol-2-yl)-2-(5-bromo-2-oxoindolin-3-ylidene)hydrazinecarboxamide against doxorubicin induced cardiotoxicity in rats

Abstract

The present study was aimed to evaluate the cardioprotective activity of N-(benzo[d]oxazol-2-yl)-2-(5-bromo-2-oxoindolin-3-ylidene)hydrazinecarboxamide (coded as ARL) in rats. Doxorubicin (DOX) (15 mg kg⁻¹, i.p, single dose) was used to induce cardiotoxicity in rats. Four groups of female Wistar albino rats were used. Group 1 was used as control (0.5% CMC, oral); the other groups were treated with DOX (single i.p. dosage of 15 mg kg⁻¹) or DOX plus compound ARL (50 or 100 mg kg⁻¹ day⁻¹, p.o.), respectively. Animals were treated with ARL or CMC for 7 days. On 6th day, a single dose of DOX was administered to rats. Blood was collected on 7th day. Evaluation of cardioprotective activity was estimated using biochemical parameters including plasma aspartate aminotransferase, creatine kinase (CK-MB), lactate dehydrogenase (LDH), and triglycerides (TG) levels. Pretreatment with compound ARL significantly reduced the elevated levels of cardiotoxic biomarkers in plasma. DOX-induced depletion of glutathione levels in blood was significantly alleviated by pretreatment with compound ARL.

Keywords:

• cardiotoxicity
• N-(benzo[d]oxazol-2-yl)-2-(5-bromo-2-oxoindolin-3-ylidene)hydrazinecarboxamide
• cardioprotective
• doxorubicin
• LDH
• CK-MB
• AST
• TG

Acknowledgments

All authors are gratefully indebted to Dr G. Sreenivas Reddy, Secretary, Vaageswari College of Pharmacy, Karimnagar, AP, India, for providing necessary facilities to carry out my work and for his constant support and encouragement and very much grateful to Dr G. Anand, MD (pathologist), Prathima Institute of Medical Sciences, Karimnagar, AP, India, for providing histopathological reports and his kind help for the successful completion of this work.